Showing 261-270 of 355 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| An AI-driven bioelectronics system to accelerate SC-islet maturation | Trustees of the University of Pennsylvania | Juan Alvarez | Cures | 01-April-2025 to 01-March-2027 | $200.000,00 |
| A bioelectronics platform to standardize SC-islet maturation and model T1D autoimmunity | Trustees of the University of Pennsylvania | Juan Alvarez | Cures | 01-October-2026 to 30-September-2029 | $1.049.999,94 |
| Evaluating gene-modified hypo-immune PSCs for immune evasion in NHPs | Trustees of the University of Pennsylvania | Ji Lei | Cures | 01-June-2025 to 31-May-2027 | $749.999,08 |
| Engineering regulatory B cells to promote immune tolerance for islet cell replacement therapy: A novel opportunity to cure Type I diabetes | Trustees of the University of Pennsylvania | James Markmann | Cures | 01-October-2026 to 30-September-2029 | $598.995,17 |
| Prevalence of Endogenous Hypercortisolism in People with poorly controlled Type 1 Diabetes: Hypercortisolism In Type 1 DM (HIT-T1D) | Tulane University | Vivian Fonseca | Improving Lives | 01-October-2026 to 30-September-2029 | $2.309.103,00 |
| Reducing the Burden of Type 1 Diabetes Using Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances | University of California, San Diego | Schafer Boeder | Improving Lives | 01-July-2022 to 30-June-2027 | $749.956,58 |
| Assessment of impaired counterregulatory hormones and endothelial dysfunction using wearable sensors in people living with type 1 diabetes | University of California, San Diego | Robert Thomas | Improving Lives | 01-June-2026 to 31-May-2031 | $999.888,08 |
| IL-37 expressing Treg cells to improve T1D therapeutic strategy | University of California, San Diego | Mayumi Fujita | Cures | 01-September-2025 to 28-February-2027 | $161.904,81 |
| Microneedle Sensor for Simultaneous Continuous Monitoring of Ketone and Glucose | University of California, San Diego | Joseph Wang | Improving Lives | 01-October-2022 to 30-April-2027 | $867.998,91 |
| The Effects of Glucagon Antagonism on Insulin Resistance, Ketone Production, and Cardiovascular Risk in Individuals with Type 1 Diabetes | University of California, San Diego | Jeremy Pettus | Improving Lives | 01-June-2021 to 30-November-2026 | $1.233.752,52 |